Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis

Journal of Immunology

Volumn 192, Issue 7, 2014, Pages 3111-3120

  Cheuk, Stanley ^a   Wikén, Maria ^a   Blomqvist, Lennart ^a   Nylén, Susanne ^a   Talme, Toomas ^a   Ståhle, Mona ^a   Eidsmo, Liv ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA1 INTEGRIN; CD103 ANTIGEN; CHEMOKINE RECEPTOR CCR6; INTERLEUKIN 12; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 23 RECEPTOR; LYMPHOCYTE ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL POPULATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; EPIDERMIS CELL; EX VIVO STUDY; GENE EXPRESSION; HELPER CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MEMORY T LYMPHOCYTE; NARROW BAND IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; RECURRENT DISEASE; SIGNAL TRANSDUCTION; TC17 CELL; TH22 T CELL; ULTRAVIOLET B RADIATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD; DERMATOLOGIC AGENTS; EPIDERMIS; FLOW CYTOMETRY; HUMANS; IMMUNOLOGIC MEMORY; INTEGRIN ALPHA CHAINS; INTERLEUKIN-17; INTERLEUKINS; MICROSCOPY, CONFOCAL; MIDDLE AGED; MODELS, IMMUNOLOGICAL; PSORIASIS; RECEPTORS, CCR6; RECEPTORS, INTERLEUKIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; TRANSCRIPTOME; ULTRAVIOLET RAYS; YOUNG ADULT;

EID: 84897495287     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1302313     Document Type: Article

References (44)

1. Conrad, C., O. Boyman, G. Tonel, A. Tun-Kyi, U. Laggner, A. de Fougerolles, V. Kotelianski, H. Gardner, and F. O. Nestle. 2007. α1β1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. Nat. Med. 13: 836-842.
2. Res, P. C. M., G. Piskin, O. J. de Boer, C. M. van der Loos, P. Teeling, J. D. Bos, and M. B. M. Teunissen. 2010. Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One 5: e14108.
3. Lowes, M. A., T. Kikuchi, J. Fuentes-Duculan, I. Cardinale, L. C. Zaba, A. S. Haider, E. P. Bowman, J. G. Krueger, L. C. Zaba, L. C. Zaba, et al. 2008. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J. Invest. Dermatol. 128: 1207-1211.
4. Ma, H. L., S. Liang, J. Li, L. Napierata, T. Brown, S. Benoit, M. Senices, D. Gill, K. Dunussi-Joannopoulos, M. Collins, et al. 2008. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J. Clin. Invest. 118: 597-607.
5. Leonardi, C. L., A. B. Kimball, K. A. Papp, N. Yeilding, C. Guzzo, Y. Wang, S. Li, L. T. Dooley, K. B. Gordon, and PHOENIX 1 study investigators. 2008. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, doubleblind, placebo-controlled trial (PHOENIX 1). Lancet 371: 1665-1674.
6. Leonardi, C., R. Matheson, C. Zachariae, G. Cameron, L. Li, E. Edson-Heredia, D. Braun, and S. Banerjee. 2012. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N. Engl. J. Med. 366: 1190-1199.
7. Papp, K. A., C. Leonardi, A. Menter, J. P. Ortonne, J. G. Krueger, G. Kricorian, G. Aras, J. Li, C. B. Russell, E. H. Thompson, and S. Baumgartner. 2012. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N. Engl. J. Med. 366: 1181-1189.
8. Hueber, W., D. D. Patel, T. Dryja, A. M. Wright, I. Koroleva, G. Bruin, C. Antoni, Z. Draelos, M. H. Gold, P. Durez, et al. 2010. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Transl. Med. 2: 52ra72.
9. Suárez-Fariñas, M., J. Fuentes-Duculan, M. A. Lowes, and J. G. Krueger. 2011. Resolved psoriasis lesions retain expression of a subset of disease-related genes. J. Invest. Dermatol. 131: 391-400.
10. Clark, R. A., B. Chong, N. Mirchandani, N. K. Brinster, K. Yamanaka, R. K. Dowgiert, and T. S. Kupper. 2006. The vast majority of CLA+ T cells are resident in normal skin. J. Immunol. 176: 4431-4439.
11. Seneschal, J., R. A. Clark, A. Gehad, C. M. Baecher-Allan, and T. S. Kupper. 2012. Human epidermal Langerhans cells maintain immune homeostasis in skin by activating skin resident regulatory T cells. Immunity 36: 873-884.
12. Gebhardt, T., L. M. Wakim, L. Eidsmo, P. C. Reading, W. R. Heath, and F. R. Carbone. 2009. Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. Nat. Immunol. 10: 524-530.
13. Zhu, J., D. M. Koelle, J. Cao, J. Vazquez, M. L. Huang, F. Hladik, A. Wald, and L. Corey. 2007. Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J. Exp. Med. 204: 595-603.
14. Mackay, L. K., A. T. Stock, J. Z. Ma, C. M. Jones, S. J. Kent, S. N. Mueller, W. R. Heath, F. R. Carbone, and T. Gebhardt. 2012. Long-lived epithelial immunity by tissue-resident memory T (TRM) cells in the absence of persisting local antigen presentation. Proc. Natl. Acad. Sci. USA 109: 7037-7042.
15. Casey, K. A., K. A. Fraser, J. M. Schenkel, A. Moran, M. C. Abt, L. K. Beura, P. J. Lucas, D. Artis, E. J. Wherry, K. Hogquist, et al. 2012. Antigen-independent differentiation and maintenance of effector-like resident memory T cells in tissues. J. Immunol. 188: 4866-4875.
16. Eidsmo, L., A. T. Stock, W. R. Heath, S. Bedoui, and F. R. Carbone. 2012. Reactive murine lymph nodes uniquely permit parenchymal access for T cells that enter via the afferent lymphatics. J. Pathol. 226: 806-813.
17. Tasew, G., S. Nylén, T. Lieke, B. Lemu, H. Meless, N. Ruffin, D. Wolday, A. Asseffa, H. Yagita, S. Britton, et al. 2010. Systemic FasL and TRAIL neutralisation reduce leishmaniasis induced skin ulceration. PLoS Negl. Trop. Dis. 4: e844.
18. Hijnen, D., E. F. Knol, Y. Y. Gent, B. Giovannone, S. J. Beijn, T. S. Kupper, C. A. Bruijnzeel-Koomen, and R. A. Clark. 2013. CD8+ T cells in the lesional skin of atopic dermatitis and psoriasis patients are an important source of IFN-g, IL-13, IL-17, and IL-22. J. Invest. Dermatol. 133: 973-979.
19. Molin, L., and Calcipotriol-UVB Study Group. 1999. Topical calcipotriol combined with phototherapy for psoriasis: the results of two randomized trials and a review of the literature. Dermatology 198: 375-381.
20. Gottlieb, A. B., R. Evans, S. Li, L. T. Dooley, C. A. Guzzo, D. Baker, M. Bala, C. W. Marano, and A. Menter. 2004. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol. 51: 534-542.
21. Reich, K., G. Wozel, H. Zheng, H. J. van Hoogstraten, and L. Flint. 2013. Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a Randomised, Long-Term Extension Trial (RESTORE2). Br. J. Dermatol. 168: 1325-1334.
22. Weaver, C. T., C. O. Elson, L. A. Fouser, and J. K. Kolls. 2013. The Th17 pathway and inflammatory diseases of the intestines, lungs, and skin. Annu. Rev. Pathol. 8: 477-512.
23. Zhernakova, A., C. C. van Diemen, and C. Wijmenga. 2009. Detecting shared pathogenesis from the shared genetics of immune-related diseases. Nat. Rev. Genet. 10: 43-55.
24. Vollmer, S., A. Menssen, and J. C. Prinz. 2001. Dominant lesional T cell receptor rearrangements persist in relapsing psoriasis but are absent from nonlesional skin: evidence for a stable antigen-specific pathogenic T cell response in psoriasis vulgaris. J. Invest. Dermatol. 117: 1296-1301.
25. Menssen, A., P. Trommler, S. Vollmer, D. Schendel, E. Albert, L. Gürtler, G. Riethmüller, and J. C. Prinz. 1995. Evidence for an antigen-specific cellular immune response in skin lesions of patients with psoriasis vulgaris. J. Immunol. 155: 4078-4083.
26. Austin, L. M., M. Ozawa, T. Kikuchi, I. B. Walters, and J. G. Krueger. 1999. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-g, interleukin-2, and tumor necrosis factor-a, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J. Invest. Dermatol. 113: 752-759.
27. Ozawa, M., K. Ferenczi, T. Kikuchi, I. Cardinale, L. M. Austin, T. R. Coven, L. H. Burack, and J. G. Krueger. 1999. 312-nanometer ultraviolet B light (narrow-band UVB) induces apoptosis of T cells within psoriatic lesions. J. Exp. Med. 189: 711-718.
28. Mitsui, H., M. Suárez-Fariñas, D. A. Belkin, N. Levenkova, J. Fuentes-Duculan, I. Coats, H. Fujita, and J. G. Krueger. 2012. Combined use of laser capture microdissection and cDNA microarray analysis identifies locally expressed disease-related genes in focal regions of psoriasis vulgaris skin lesions. J. Invest. Dermatol. 132: 1615-1626.
29. Zaba, L. C., M. Suárez-Fariñas, J. Fuentes-Duculan, K. E. Nograles, E. Guttman-Yassky, I. Cardinale, M. A. Lowes, and J. G. Krueger. 2009. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J. Allergy Clin. Immunol. 124: 1022-10.e1-395.
30. Nograles, K. E., L. C. Zaba, E. Guttman-Yassky, J. Fuentes-Duculan, M. Suárez-Fariñas, I. Cardinale, A. Khatcherian, J. Gonzalez, K. C. Pierson, T. R. White, et al. 2008. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br. J. Dermatol. 159: 1092-1102.
31. Zheng, Y., D. M. Danilenko, P. Valdez, I. Kasman, J. Eastham-Anderson, J. Wu, and W. Ouyang. 2007. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445: 648-651.
32. Duhen, T., R. Geiger, D. Jarrossay, A. Lanzavecchia, and F. Sallusto. 2009. Production of interleukin 22 but not interleukin 17 by a subset of human skinhoming memory T cells. Nat. Immunol. 10: 857-863.
33. Clark, R. A., R. Watanabe, J. E. Teague, C. Schlapbach, M. C. Tawa, N. Adams, A. A. Dorosario, K. S. Chaney, C. S. Cutler, N. R. Leboeuf, et al. 2012. Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. Sci. Transl. Med. 4: 117ra117.
34. Mizukawa, Y., Y. Yamazaki, Y. Teraki, J. Hayakawa, K. Hayakawa, H. Nuriya, M. Kohara, and T. Shiohara. 2002. Direct evidence for interferon-γ production by effector-memory-type intraepidermal T cells residing at an effector site of immunopathology in fixed drug eruption. Am. J. Pathol. 161: 1337-1347.
35. Zhu, J., T. Peng, C. Johnston, K. Phasouk, A. S. Kask, A. Klock, L. Jin, K. Diem, D. M. Koelle, A. Wald, et al. 2013. Immune surveillance by CD8αα+ skinresident T cells in human herpes virus infection. Nature 497: 494-497.
36. Schenkel, J. M., K. A. Fraser, V. Vezys, and D. Masopust. 2013. Sensing and alarm function of resident memory CD8 T cells. Nat. Immunol. 14: 509-513.
37. Green, C., J. Ferguson, T. Lakshmipathi, and B. E. Johnson. 1988. 311 nm UVB phototherapy-an effective treatment for psoriasis. Br. J. Dermatol. 119: 691-696.
38. Krueger, J. G., J. T. Wolfe, R. T. Nabeya, V. P. Vallat, P. Gilleaudeau, N. S. Heftler, L. M. Austin, and A. B. Gottlieb. 1995. Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells. J. Exp. Med. 182: 2057-2068.
39. Haider, A. S., J. Cohen, J. Fei, L. C. Zaba, I. Cardinale, K. Toyoko, J. Ott, and J. G. Krueger. 2008. Insights into gene modulation by therapeutic TNF and IFNγ antibodies: TNF regulates IFNγ production by T cells and TNF-regulated genes linked to psoriasis transcriptome. J. Invest. Dermatol. 128: 655-666.
40. Kagami, S., H. L. Rizzo, J. J. Lee, Y. Koguchi, and A. Blauvelt. 2010. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J. Invest. Dermatol. 130: 1373-1383.
41. Salem, S. A., M. A. Barakat, and C. M. Morcos. 2010. Bath psoralen+ultraviolet A photochemotherapy vs. narrow band-ultraviolet B in psoriasis: a comparison of clinical outcome and effect on circulating T-helper and T-suppressor/cytotoxic cells. Photodermatol. Photoimmunol. Photomed. 26: 235-242.
42. Sigmundsdottir, H., A. Johnston, J. E. Gudjonsson, and H. Valdimarsson. 2005. Narrowband-UVB irradiation decreases the production of pro-inflammatory cytokines by stimulated T cells. Arch. Dermatol. Res. 297: 39-42.
43. Johnson-Huang, L. M., M. Suárez-Fariñas, M. Sullivan-Whalen, P. Gilleaudeau, J. G. Krueger, and M. A. Lowes. 2010. Effective narrow-band UVB radiation therapy suppresses the IL-23/IL-17 axis in normalized psoriasis plaques. J. Invest. Dermatol. 130: 2654-2663.
44. Rácz, E., E. P. Prens, D. Kurek, M. Kant, D. de Ridder, S. Mourits, E. M. Baerveldt, Z. Ozgur, W. F. J. van IJcken, J. D. Laman, et al. 2011. Effective treatment of psoriasis with narrow-band UVB phototherapy is linked to suppression of the IFN and Th17 pathways. J. Invest. Dermatol. 131: 1547-1558.